HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AM4113

a cannabinoid CB1 receptor neutral antagonist

Networked: 17 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - AM4113: 17

Experts

1.	Makriyannis, Alexandros: 9 articles (02/2021 - 12/2007)
2.	Vemuri, Kiran: 7 articles (02/2021 - 03/2008)
3.	Vemuri, V Kiran: 4 articles (02/2013 - 12/2007)
4.	Bergman, Jack: 3 articles (01/2016 - 03/2008)
5.	Thakur, Ganesh A: 3 articles (02/2013 - 03/2008)
6.	Aldawsari, Hibah M: 2 articles (02/2021 - 10/2020)
7.	Eid, Basma G: 2 articles (02/2021 - 10/2020)
8.	El-Bassossy, Hany M: 2 articles (02/2021 - 10/2020)
9.	Hanafy, Abeer: 2 articles (02/2021 - 10/2020)
10.	Neamatallah, Thikryat: 2 articles (02/2021 - 10/2020)

Related Diseases

1.	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/06/2021 - "This study investigated the effects of two neutral CB1 receptor antagonists, AM6545 and AM4113, on nephropathy associated with metabolic syndrome (MetS). " 11/03/2023 - "Effects of the CB1 receptor antagonists AM6545 and AM4113 on metabolic syndrome-induced prostatic hyperplasia in rats." 02/06/2021 - "Interference with TGFβ1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome." 10/29/2020 - "Effects of the CB1 Receptor Antagonists AM6545 and AM4113 on Insulin Resistance in a High-Fructose High-Salt Rat Model of Metabolic Syndrome."
2.	Inflammation (Inflammations) 07/14/2023 - "Elevated dorsal root ganglion neuronal activity after injury was also diminished in rats by mPFC injection of AM4113, potentially by reducing antidromic activity and subsequent neuronal inflammation. " 02/06/2021 - "In conclusion, AM6545 and AM4113, possess reno-protective effects by interfering with TGFβ1-mediated renal inflammation and fibrosis, via peripheral action." 02/06/2021 - "Interference with TGFβ1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome."
3.	Weight Loss (Weight Reduction) 12/01/2016 - "The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability."
4.	Tobacco Use Disorder (Nicotine Dependence) 12/01/2016 - "The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability."
5.	Fibrosis (Cirrhosis) 02/06/2021 - "In conclusion, AM6545 and AM4113, possess reno-protective effects by interfering with TGFβ1-mediated renal inflammation and fibrosis, via peripheral action." 02/06/2021 - "Interference with TGFβ1-Mediated Inflammation and Fibrosis Underlies Reno-Protective Effects of the CB1 Receptor Neutral Antagonists AM6545 and AM4113 in a Rat Model of Metabolic Syndrome."

Related Drugs and Biologics

1.	Rimonabant
2.	CB1 Cannabinoid Receptor (CB1 Receptor)
3.	AM6545
4.	Ondansetron (Zofran)
5.	Mifepristone (RU 486)
6.	Sodium Oxybate (gamma Hydroxybutyrate)
7.	Oxytocin (Pitocin)
8.	Neuropeptides
9.	Neuropeptide Y
10.	Memantine (Namenda)

Related Therapies and Procedures

1.	Analgesia
2.	Oral Administration